KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pfizer (PFE) Income from Non-Controlling Interests (2016 - 2025)

Pfizer (PFE) has disclosed Income from Non-Controlling Interests for 17 consecutive years, with $18.0 million as the latest value for Q2 2025.

  • On a quarterly basis, Income from Non-Controlling Interests rose 157.14% to $18.0 million in Q2 2025 year-over-year; TTM through Jun 2025 was $39.0 million, a 18.18% increase, with the full-year FY2025 number at $41.0 million, up 32.26% from a year prior.
  • Income from Non-Controlling Interests was $18.0 million for Q2 2025 at Pfizer, up from $6.0 million in the prior quarter.
  • In the past five years, Income from Non-Controlling Interests ranged from a high of $47.0 million in Q4 2021 to a low of $6.0 million in Q2 2022.
  • A 5-year average of $13.2 million and a median of $9.0 million in 2021 define the central range for Income from Non-Controlling Interests.
  • Peak YoY movement for Income from Non-Controlling Interests: skyrocketed 487.5% in 2021, then crashed 76.92% in 2022.
  • Pfizer's Income from Non-Controlling Interests stood at $47.0 million in 2021, then plummeted by 87.23% to $6.0 million in 2022, then skyrocketed by 50.0% to $9.0 million in 2023, then dropped by 11.11% to $8.0 million in 2024, then soared by 125.0% to $18.0 million in 2025.
  • Per Business Quant, the three most recent readings for PFE's Income from Non-Controlling Interests are $18.0 million (Q2 2025), $6.0 million (Q1 2025), and $8.0 million (Q4 2024).